California State Teachers Retirement System Sells 5,693 Shares of Biogen Inc. $BIIB

California State Teachers Retirement System cut its stake in Biogen Inc. (NASDAQ:BIIB) by 2.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 220,687 shares of the biotechnology company’s stock after selling 5,693 shares during the period. California State Teachers Retirement System’s holdings in Biogen were worth $40,459,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP raised its holdings in Biogen by 18.3% in the 1st quarter. Quantinno Capital Management LP now owns 116,374 shares of the biotechnology company’s stock valued at $21,335,000 after acquiring an additional 18,041 shares during the period. SummitTX Capital L.P. acquired a new stake in Biogen during the first quarter worth approximately $3,970,000. Orbimed Advisors LLC bought a new stake in shares of Biogen during the first quarter worth approximately $11,293,000. OMERS ADMINISTRATION Corp boosted its holdings in shares of Biogen by 19.9% during the first quarter. OMERS ADMINISTRATION Corp now owns 20,149 shares of the biotechnology company’s stock worth $3,694,000 after acquiring an additional 3,341 shares during the period. Finally, Lombard Odier Asset Management Switzerland SA acquired a new position in shares of Biogen in the first quarter valued at approximately $715,000. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

BIIB stock opened at $202.95 on Friday. The company has a market capitalization of $29.99 billion, a P/E ratio of 35.92, a PEG ratio of 6.43 and a beta of 0.16. The company has a fifty day moving average price of $201.23 and a 200-day moving average price of $190.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.41 and a current ratio of 1.87. Biogen Inc. has a 52-week low of $124.56 and a 52-week high of $219.72.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts expect that Biogen Inc. will post 12.49 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Wedbush upped their price target on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Sanford C. Bernstein dropped their price objective on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biogen presently has a consensus rating of “Moderate Buy” and a consensus target price of $223.36.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.